logo-loader
RNS
viewGlaxoSmithKline PLC

GlaxoSmithKline PLC - Block listing Interim Review

RNS Number : 9474N
GlaxoSmithKline PLC
26 May 2020
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 May 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 November 2019

To:

30 April 2020

Balance of unallotted securities under scheme(s) from previous return:

153,724

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

370,000

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

388,348

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

135,376

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

  

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 May 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares

Period of return:

From:

1 November 2019

To:

30 April 2020

Balance of unallotted securities under scheme(s) from previous return:

835,095

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

581,004

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

254,091

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 May 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - ADS

Period of return:

From:

1 November 2019

To:

30 April 2020

Balance of unallotted securities under scheme(s) from previous return:

5,391,416

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

698,736

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

4,692,680

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 26 May 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 November 2019

To:

30 April 2020

Balance of unallotted securities under scheme(s) from previous return:

2,145,812

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

698,407

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,447,405

         

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRDZGZKGVLGGZM

Quick facts: GlaxoSmithKline PLC

Price: 1615.8

Market: LSE
Market Cap: £81.06 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE